TELINAVIR


Synonyms	NSC-670881 SC-52151 Telinavir
Status
Molecule Category	UNKNOWN
UNII	IZF55EH3CG


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	ZILOOGIOHVCEKS-HZFUHODCSA-N
Smiles	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1)C(=O)NC(C)(C)C
InChI	InChI=1S/C33H44N6O5/c1-21(2)19-39(32(44)38-33(3,4)5)20-28(40)26(17-22-11-7-6-8-12-22)36-31(43)27(18-29(34)41)37-30(42)25-16-15-23-13-9-10-14-24(23)35-25/h6-16,21,26-28,40H,17-20H2,1-5H3,(H2,34,41)(H,36,43)(H,37,42)(H,38,44)/t26-,27-,28+/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C33H44N6O5
Molecular Weight	604.75
AlogP	2.76
Hydrogen Bond Acceptor	6.0
Hydrogen Bond Donor	5.0
Number of Rotational Bond	13.0
Polar Surface Area	166.75
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	44.0

Bioactivity

Mechanism of Action	Action	Reference
HIV-1 protease inhibitor	INHIBITOR	Other PubMed PubMed

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Protease Aspartic protease Aspartic protease AA clan Aspartic protease A2A subfamily	-	6	-	-	-
Enzyme Protease Cysteine protease Cysteine protease PAC clan Cysteine protease C3A subfamily	21	6	-	-	-

Assay Description	Organism	Bioactivity
Effective concentration necessary to inhibit 50% HIV-induced cell death.	Human immunodeficiency virus 1	21.0 nM
Inhibition of HIV-1 Protease.	None	6.0 nM
Inhibition of HIV-1 protease by spectrofluorometric assay	Human immunodeficiency virus 1	6.3 nM

Related Entries

Cross References

Resources	Reference
ChEMBL	CHEMBL322241
DrugBank	DB12178
FDA SRS	IZF55EH3CG
PubChem	382974
SureChEMBL	SCHEMBL623164

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).